(Q39094846)

9 September 2017

Adverse cutaneous reactions to thiacetazone for tuberculosis treatment in Tanzania (English)

1 reference

9 September 2017

0 references

0 references

Y A Ipuge

1

1 reference

9 September 2017

H L Rieder

series ordinal

2

1 reference

9 September 2017

D A Enarson

series ordinal

3

1 reference

9 September 2017

language of work or name

English

0 references

publication date

1 September 1995

1 reference

9 September 2017

1 reference

9 September 2017

346

1 reference

9 September 2017

8976

1 reference

9 September 2017

657-660

1 reference

Isoniazid with thiacetazone (thioacetazone) in the treatment of pulmonary tuberculosis in East Africa--third investigation: the effect of an initial streptomycin supplement

9 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992278-4

7 January 2021

Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report. Third East African/British Medical Research Council Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992278-4

7 January 2021

Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992278-4

7 January 2021

An international co-operative investigation into thiacetazone (thioacetazone) side-effects.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992278-4

7 January 2021

Fatal Toxic Epidermal Necrolysis During Prophylaxis With Pyrimethamine and Sulfadoxine in a Human Immunodeficiency Virus—Infected Person

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992278-4

7 January 2021

Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992278-4

7 January 2021

Human immunodeficiency virus type-1 infection in Zambian children with tuberculosis: changing seroprevalence and evaluation of a thioacetazone-free regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992278-4

7 January 2021

Thiacetazone--avoid like poison or use with care?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992278-4

7 January 2021

Cutaneous reactions to thiacetazone in Zambia--implications for tuberculosis treatment strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992278-4

7 January 2021

HIV infection in patients with tuberculosis in Kinshasa, Zaire

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992278-4

7 January 2021

Impact of HIV on tuberculosis in Zambia: a cross sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992278-4

7 January 2021

The influence of human immunodeficiency virus infection on tuberculosis in Kampala, Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992278-4

7 January 2021

Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992278-4

7 January 2021

The global tuberculosis situation and the new control strategy of the World Health Organization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992278-4

7 January 2021

Critical assessment of smear-positive pulmonary tuberculosis patients after chemotherapy under the district tuberculosis programme.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992278-4

7 January 2021

10.1016/S0140-6736(95)92278-4

Identifiers

DOI

1 reference

9 September 2017

1 reference